1744 results about "Breast cancer cells" patented technology

Human breast tumors contain hetrogeneous cancer cells. using an animal xenograft model in which human breast cancer cells were grown in immunocompromised mice we found that only a small minority of breast cancer cells had capacity to form new tumors. The ability to form new tumors was not a slochastic property, rather certain populations of cancer cells were depleted for the ability to form new tumors, while other populations were enriched for the ability to form new tumors. Tumorigenic cells could be distinguished from non-tumorigenic cancer cells based on surface marker expression. We prospectively identified and isolated the tumorigenic cells as CD44³⁰CD24^−/lowLINEAGE A few as 100 cells from this population were able to form tumors the animal xenograft model, while tens of thousands of cells from non-tumorigenic populations failed to form tumors. The tumorigenic cells could be serially passaged, each time generating new tumors containing and expanded numbers of CD44^+CD24 Lineage tumorigenic cells as well as phenotypically mixed populations of non-tumorigenic cancer cells. This is reminiscent of the ability of normal stem cells to self-renew and differentiate. The expression of potential therapeutic targets also differed between the tumorigenic and non-tumorigenic populations. Notch activation promoted the survival of the tumorigenic cells, and a blocking antibody against Notch 4 induced tumorigenic breast cancer cells to undergo apoptosis.

The present invention relates to a novel gene, Di12, that is differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell lines, and in several normal tissues. The full length cDNA encodes a protein of 339 amino acids. Antibodies to the gene product were developed to investigate the expression of Di12 in breast cancer cell-lines and tumors. The Di12 protein was found in tissue sections of infiltrating ductal carcinomas (IDCs), but not in benign or normal breast specimens. Di12 wag also present in IDC-breast cancer patient sera, and its expression level increased markedly if IDC was accompanied by lymph node or distal metastases. As IDC constitutes ~70% of breast cancers seen clinically, the level of Di12 expression is useful for diseases diagnosis predicting disease progression and monitoring a therapeutic treatment.

The invention discloses a breast cancer cell characteristic analysis system based on deep learning. Based on the deep learning, the system constructs a multilevel convolutional neural network to extract multilevel features, so higher analysis accuracy can be realized; an activation function of a model in the breast cancer cell characteristic analysis system disclosed by the invention is an unsaturated ReLU function, which has faster convergence properties; a pooling layer in the breast cancer cell characteristic analysis system disclosed by the invention adopts an overlapped pooling operation, it can be proved by cross validation that, compared with a traditional non-overlapped pooling layer, the overlapped pooling can further improve the analysis accuracy; and the breast cancer cell characteristic analysis system disclosed by the invention adopts a training mode of sparse autocoder pre-training and Dropout fine tuning to effectively reduce the over fitting of the model and enhance the generalization ability of the trained model, so that the analysis accuracy can be further improved.

The invention relates to combinations comprising an HDAC inhibitor and a Her2 inhibitor for the treatrent of breast cancer in a subject in need thereof. The invention also relates to combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof. Also provided herein are methods for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. Further provided are methods for inhibiting migration and/or invasion of a breast cancer cell in a subject by administering to the subject a HDAC6 specific inhibitor.

The invention relates to synthesis of benzimidazole-containing naphthalimide derivatives and applications of the benzimidazole-containing naphthalimide derivatives on cancer resistance, and belongs to the field of organic synthesis and pharmaceutical chemistry technology. The benzimidazole-containing naphthalimide derivatives are obtained through a method that a benzimidazole group is introduced into a fourth position of a naphthalene ring of naphthalimide. Experiments of proliferation inhibiting effects of the benzimidazole-containing naphthalimide derivatives on cancer cells adopt a microculture tetrozolium (MTT) reduction method and aim at MCF-7 human breast cancer cells, Hela human cervical cancer cells and PC12 rat adrenal medullary pheochromocytoma differentiated cells. Results of the experiments show that the benzimidazole-containing naphthalimide derivatives have the advantages of good inhibitory activity against cancer cells and good selectivity on cancer cells.

The invention relates to an endogenous protein marking method applied to genome-wide binding spectrum analysis. The method comprises the steps of designing sgRNA for upstream and downstream 50bp regions of an encoding termination site of an NCOA1 gene; verifying cutting efficiency of sgRNA mediated Cas9 by an experiment; building an anti-estrogen therapy tolerant MCF-7 breast cancer cell model; by utilizing a CRISPR/Cas9 homologous recombination technology, selecting and using effective sgRNA and DNA donors, and introducing a Flag tag in the 3' end of the ER alpha co-transcription factor NCOA1 gene; and establishing a stable cell line with the Flag tag. Compared with the prior art, the method has the advantages that gene editing is performed by utilizing the CRISPR/Cas9 technology, so that the tag insertion efficiency of the gene editing is greatly improved; more importantly, chromatin structure parameters are introduced for designing sgRNA, so that effective cutting of Cas9 at a target site of a genome is ensured; and positive clone screening is performed by adopting DNA sequencing and RT-PCR sequencing methods, so that the positive clone identification step is simplified and the manpower and material resources for screening are reduced.

The invention relates to the technical field of gene transfer materials, particularly a preparation method of nano sulfonated graphene and application of nano sulfonated graphene as a gene transfer material. The preparation method of the nano sulfonated graphene comprises the following steps: 1. preparing graphene oxide; 2. preparing reduced graphene oxide; 3. preparing diazonium salt of sulfanilic acid; and 4. preparing the nano sulfonated graphene. The nano sulfonated graphene can be used as a gene transfer material since positive charges of ions on particle surfaces can be combined with green fluorescent proteins in a non-covalent mode to perform transfection; and when being used as a gene transfer material, the nano sulfonated graphene has the advantages of high transfection effect, favorable cell compatibility and high cell survival rate. The transfection efficiency of the nano sulfonated graphene in human breast cancer cells is up to 40% or so.

The invention relates to a DNA-targeted o-dicyano-acenaphtho pyrazine compound in the field of application of antineoplastic medicaments. The compound is prepared by taking acenaphthene quinone as a raw material and performing bromination, cyclization and aromatic nucleophilic substitution reaction. The compound is characterized in that: one end takes an amino straight chain of a flexible side chain or an annular group as an electron-donating group, while the other end takes two cyanogen groups as electron-withdrawing groups; the two ends form an electron deficient large-plane conjugated system; and the structure accords with an ideal DNA intercalator. The compound shows obvious inhibitory activity to an in vitro test of MCF-7 (human mammary cancer cells).

The invention provides a classification method and a classification system for cancer digital pathological cell images. According to the classification method and the classification system, a suspected lesion region of interest is subjected to block processing, the suspected lesion region after block processing is subjected to feature extraction by utilizing partial matching pattern textural features, and the extracted features are classified and identified by adopting an extreme learning machine training method, so as to determine benign and malignant tumors and differentiate levels. The classification method and the classification system for the cancer digital pathological cell images utilize the partial matching pattern textural features for conducting feature extraction, analyze the textural features of cells from macroscopic and microscopic aspects, have the advantage of rotation invariance, effectively overcome the problems of diversity, irregularity and the like of cell morphology, provide reliable textural feature information for classification, apply an extreme learning machine to the classification of breast cancer cells, shorten the training time, accelerate the speed of classification and identification, and improve the accuracy of recognition.

The present invention features a novel use of processed ingredients from the Indian mulberry plant. More specifically, the present invention features a novel use of processed Morinda citrifolia, namely Morinda citrifolia fruit juice, puree, or puree juice for treating breast cancer, and particularly for inhibiting and/or preventing the metastasis of carcinogenic cells within the mammary region of the breast, as well as destroying metastasized mammary or breast cancer cells. The present invention comprises the consumption of food products or medicinal products or compositions comprising processed Morinda citrifolia, in either puree or fruit juice form. The present invention also features a method of inhibiting carcinogen-mediated conversion of mammary cells and protecting DNA against carcinogen-mediated damage by administering a composition comprising water soluble Morinda citrifolia.

A water soluble extract from a plant of Solanum genus consists essentially of at least 60%–90% of solamargine and solasonine. A process for preparing the water soluble extract from the plant of Solanum genus involves the steps of hydrolysis with an acid, precipitation with a base, and separation treatments using chloroform, alcohol and water as extraction solvents. The water soluble extract prepared from the process can be directly dissolved in pure or neutral pH water to form a yellowish clear and transparent aqueous solution having a water solubility ranging from 2˜20 mg/ml or higher.

The water soluble extract can be used as an active component in a pharmaceutical composition for inhibiting the growth of tumor/cancer cells, in particular liver cancer cells, lung cancer cells and breast cancer cells.

The invention discloses a class of anti-tumor compounds containing a triazole heterocyclic structure and an application thereof, belonging to the technical field of medicinal chemistry. The compounds containing the triazole heterocyclic structure introduce quintuple 1,2,3-triazole ring in the form of side chains through the amino condensation, bromination, nitrine substitution, link reaction and other reactions on the basis of naphthalimide parent structure, select tetrazolium salt reduction to test 7721 hepatocellular in the experiment of inhibiting proliferation of tumor cells, and also select sulfonyl rhodamine B protein staining method to test MCF-7 breast cancer cells. The experiment results show that the anti-tumor compounds have wide anti-tumor activity and good inhibition effect on the normal growth of tumor cells derived from different tissues of liver cancer, breast cancer and the like.

It is disclosed here that HMG-CoA reductase inhibitors inhibit the proliferation and cause the death of breast cancer cells by inducing the expression of inducible nitric oxide synthase (iNOS) to promote intracellular nitric oxide formation, which the inventors found to be accomplished through the inhibition of protein geranylgeranylation. The disclosure here enables a new breast cancer treatment strategy that combines the inhibition HMG-CoA reductase or protein geranylgeranylation and the promotion of nitric oxide formation by iNOS.

The invention discloses a method for separating rare cells from peripheral blood and a kit using the same. The method integrates a negative enrichment technology and a density gradient centrifugation technology, has the advantages of high recovery rate, simpleness, and convenience, and generates little damage to rare cells in peripheral blood. By using the provided kit, tumor cells such as breast cancer cells can be separated from peripheral blood through the separation method. The kit and method can also be applied to early diagnosis, relapse monitoring, and drug effect evaluation, can be used to separate rare cells in body liquids such as pleural fluid, ascitic fluid, and the like, and have a wide application prospect.

The various embodiments of the present disclosure relate generally to compositions and methods for the targeted cellular delivery of nanoparticles. More particularly, the various embodiments of the present invention are directed to the cellular delivery of nanoparticles tethered to a ligand by way of a poly(ethylene glycol) linkage, wherein the ligand demonstrates a binding specificity for a cellular target. In an exemplary embodiment, the ligand is tamoxifen and the cellular target is the estrogen receptor, which is upregulated in many breast cancer cells.

The invention provides, in part, novel SV-BR cancer cell lines. The invention provides a novel cell line SV-BR-1 deposited under ATCC ______, and SV-BR-1-GM cells deposited under ATCC ______. The invention further relates to therapeutic and non-therapeutic uses of the novel cell lines. Therapeutic uses include the use of SV-BR cell lines as cancer vaccines, and in particular, or the treatment of cancer.

The invention relates to the field of medical technologies, in particular to a lipoic-acid-modified nanometer polypeptide carrier and a preparation method and application thereof.The lipoic-acid-modified nanometer polypeptide carrier is composed of arginine, histidine, lipoic acid and cysteine.A disulfide bond contained in lipoic acid is adopted for cross-linking, a formed polypeptide polymer can be rapidly degraded in cells and will not accumulate in the cells, and arginine and cysteine in polypeptide are in-vivo amino acid and are free of toxic and side effects to the human body.A CCK-8 cell proliferation test shows that the prepared nanometer carrier has low cell toxicity and meanwhile has good capacity of co-delivery of a gene and chemotherapy drugs; the nanometer carrier can specifically enhance the sensitivity of drug-resistant cells to the chemotherapy drugs in breast cancer drug-resistant treatment and promote apoptosis of breast cancer cells, and therefore becomes a targeted, efficient and low-toxicity nanoscale delivery system in breast cancer drug-resistant treatment.

The invention provides a preparation method of a double chimeric antigen receptor gene modified T lymphocyte targeting breast cancer stem cells. The preparation method is characterized in that integrin-associated protein (CD47) and transcriptional coactivator (TAZ) are both highly expressed in breast cancer tissues, especially in the breast cancer stem cells; by established CD47 and TAZ over-expressed breast cancer cells, higher proliferation and metastasis capacity and cancer stem cell features are shown. Extracellular domain of the two breast cancer stem cell antigens CD47 and TAZ are targeted to generate monoclonal strains in specific binding under immunity action, and single-chain antibodies in specific binding with the CD47 and TAZ by genetic recombination are obtained to construct a human CD47 and TAZ containing double chimeric antigen receptor gene recombined to a virus vector to transfect human T lymphocyte. By high expression of the double chimeric antigen receptor gene in specific binding with human CD47 and TAZ expressing breast cancer stem cells, a first signal and a costimulatory signal can be activated to trigger anti-breast-cancer cytotoxicity, and high cytotoxicity in in-vivo and in-vitro anti-cancer experiments is achieved.